A Pilot Pharmacodynamic Study to Assess the Anti-proliferative Activity a of the Poly ADP Ribose Polymerase (PARP) Inhibitor Olaparib in Patients With Human Papilloma Virus (HPV) Positive and Human Papilloma Virus (HPV) Negative Head and Neck Squamous Cell Carcinoma (HNSCC)
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Olaparib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Pharmacodynamics
- 09 Jan 2020 Planned initiation date changed from 1 Jan 2016 to 1 Jan 2018.
- 09 Jan 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 11 Jan 2018 Planned End Date changed from 1 Jul 2017 to 1 Jul 2019.